-specific survival advantage over postoperative adjuvant chemotherapy in patients with stage II tumors. NSABP B-27 was a 3-arm, randomized, phase III trial of women with invasive breast cancer treated with preoperative systemic therapy with AC (doxorubicin
Search Results
William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar
Robin K. Kelley, Grace Wang, and Alan P. Venook
, his oncologist requests MMR protein testing of his tumor specimen to inform decision-making regarding adjuvant chemotherapy. His tumor is found to have deficiency in MLH1 through immunohistochemistry along with high-level MSI (MSI-H) according to PCR
John B. Eifler, Daniel A. Barocas, and Matthew J. Resnick
based on prior studies of adjuvant chemotherapy, 15 and the criteria now include results of axial imaging, examination under anesthesia, and TUR. Specifically, MD Anderson defines high-risk disease as the presence of a palpable mass or local invasion
Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Axel Grothey, Howard S. Hochster, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Lucille A. Leong, Edward Lin, Wells A. Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah Freedman-Cass
rates were seen, and induction chemotherapy seemed to be less toxic and better tolerated. Another phase II trial randomized patients to chemoRT and surgery with or without FOLFOX induction therapy; adjuvant chemotherapy was administered at the
Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer
, and patients aged 50 to 69 years received less benefit from chemotherapy than patients younger than 50 years. 108 In addition, the benefit of adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate, fluorouracil) in addition to tamoxifen
Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel
axillary lymph nodes; and, to a lesser extent, presence or absence of estrogen receptor (ER) and progesterone receptor (PR). In this paradigm, clinicians estimated the risk of recurrence and, if it was large enough, provided adjuvant chemotherapy and—if the
Huei-Ting Tsai, Claudine Isaacs, Filipa C. Lynce, Suzanne C. O'Neill, Chunfu Liu, Marc D. Schwartz, Nandini Selvam, Yingjun Zhou, and Arnold L. Potosky
combination with cytotoxic chemotherapies. 1 In January 2008, trastuzumab was approved for use as single-agent therapy after standard adjuvant chemotherapy for early-stage, HER2-positive breast cancer, independent of nodal status, based on data from the
Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung
recurrent disease. Although adjuvant chemotherapy improves survival for all patients with resected PDAC, 2 , 3 up to 50% of patients will not initiate postoperative chemotherapy, typically because of poor performance status after major surgery. 4 – 6 A
Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza
micrometastases to the bone marrow: a long-term follow-up . Ann Oncol 2008 ; 19 : 2007 – 2011 . 13. Coleman R Thorpe H Cameron D . Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy—first safety data from the
Kshama Jaiswal, Madelyne Hull, Anna L. Furniss, Reina Doyle, Natalia Gayou, and Elizabeth Bayliss
patients have a median time of 69 days to starting RT after their last surgery when no other adjuvant chemotherapy was indicated. The process of external referral to radiation oncology adds significantly to the delay (median of 22 days from referral to
